Nathan Smith’s AI-built portfolio is up 23.8% in four weeks after leveraging ChatGPT. He shares his take on micro-caps, risk, ...

Lilly is on track to file its oral GLP-1 agonist orforglipron for type 2 diabetes next year after presenting the first phase 3 data with the drug.